Boston Scientific Corporation vs QUALCOMM, Inc. — how do they compare? Boston Scientific Corporation trades at $42.6 (market cap $66.37B), while QUALCOMM, Inc. trades at $179.51 (market cap $187.72B). The key difference: QUALCOMM, Inc. is far larger — about 2.8× Boston Scientific Corporation's market cap, and QUALCOMM, Inc. pays a 2.07% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | QCOM | |
|---|---|---|
Market Cap | $66.37B | $187.72B |
Sector | Health | Technology |
52-Week High | $108.14 | $251.10 |
52-Week Low | $42.63 | $124.07 |
Enterprise Value | $75.94B | $193.19B |
Dividend Yield | — | 2.07% |
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
Qualcomm (QCOM) trades at $178.08, down 5.86% over 24 hours, with a bearish technical signal and mixed sentiment. The stock shows strong profitability with a 22.31% net income margin and consistent earnings beats in recent quarters. Recent news highlights its AI and data center diversification amid smartphone market challenges, with CEO Cristiano Amon projecting 'multiple billions' in data center revenue ahead (MarketBeat, June 2, 2026).
The outlook balances growth in AI and automotive against near-term margin pressures and competition. Analysts see upside to a $222.53 consensus target, but risks include Nvidia's entry into PC chips and soft smartphone demand. The stock offers value at a P/E of 19.78, with dividends providing income support.
Trailing returns across standard periods
Latest headlines on both assets
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G and 4G networks. The firm is a leader in 5G network technology as well. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones and chips into automotive and Internet of Things markets.
Read more on QCOM →